Introduction
Angiotensin-converting enzyme (ACE) inhibitors are a frequently used therapy for patients with hypertension. Apart from their antihypertensive effect, ACE inhibitors (ACE-I) also display cardiovascular and renoprotective effects, both in human and experimental renal diseases. 1, 2 These renoprotective effects can be monitored by studying the antiproteinuric effects of the drug. Unfortunately, ACE-I treatment does produce side-effects, such as cough, hypotension 3 and hyperkalaemia, 4 and only a limited number of patients show an optimal antiproteinuric and renoprotective response.This non-response can (partly) be overcome by several means, amongst which dosage and dietary sodium intake are important. Increasing the dose of the ACE-I will increase antiproteinuric efficacy. However, this may be at the expense of side-effects.The efficacy of ACE-I can also be enhanced by lowering the dietary sodium intake. [5] [6] [7] [8] However, compliance with a strict dietary sodium restriction is difficult for many patients in Western cultures.
We have previously found that renal selective drug targeting offers a way to gain high drug concentrations in the kidneys. For this purpose, we synthesised a conjugate of the ACE-I, captopril, with the low-molecularweight-protein, lysozyme, which was accumulated in the kidney, paralleled by an increase in renal ACE-I in comparison with systemically administered captopril. 9, 10 To investigate whether the response to ACE-I under high-sodium conditions may be enhanced by targeting the drug to the kidney, we studied the effect of captopril-lysozyme conjugate on adriamycin-induced proteinuria in rats fed with a high-sodium diet, and compared that to the efficacy of the untargeted ACE-I.
Materials and methods

Synthesis and characterisation of captopril-lysozyme
The process of synthesis and characterisation of 
Experimental animals
Animal experiments were conducted in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The Animal Experimental Committee approved all protocols. Male Wistar rats (310-325 g; n=29) were housed under standard conditions with free access to food and drinking water.
Experimental procedure
After one week of adaptation, baseline 24-hour urine samples were collected in metabolic cages. Rats were injected with adriamycin (2 mg/kg; Adriblastina R.T.U., 2 mg/ml) in the tail vein under anaesthesia with isoflurane 3% in N 2 O/O 2 (2:1) to induce proteinuria.After three weeks, the animals were put on a high-sodium diet (3.0% NaCl) (Hope Farms, Woerden, The Netherlands). From that time onwards, 24-hour-urine was collected in metabolic cages weekly. In addition, systolic blood pressure was measured weekly using tail-cuff plethysmography (IITC Life Science, Woodland Hills, CA) in awake, restrained animals. Animals with proteinuria < 80 mg/24 hours were excluded from the experiment. After stratification for proteinuria, from t=5.5 weeks onwards the animals were given the following treatments by once-daily subcutaneous injections for 10 days (all dissolved in 5% glucose): (1) vehicle (5% glucose; n=7); (2) lysozyme (76 mg/kg/24 hours, Sigma-Aldrich, St. Louis, MO, USA; n=7); (3) captopril (5 mg/kg/24 hours, Sigma-Aldrich; n=8); (4) captopril-lysozyme conjugate (equivalent to 1mg/kg/24 hours captopril and 76 mg/kg/24 hours lysozyme; n=7). After one, four, seven and nine days of treatment proteinuria was measured. After three, six and nine days of treatment, blood pressure was measured at 30 (n=2) or 60 (n=2), 120 (n=2) and 240 (n=2) minutes after the last injection. Animals were sac-rificed after 10 days of treatment at 60 (n=2 or 3) or 240 (n=5) minutes after the last injection. Laparotomy was performed under anaesthesia with isoflurane 3% in N 2 O/O 2 (2:1) and a blood sample was taken from the abdominal aorta. Kidneys were flushed with saline, removed and weighed. Kidney samples were homogenised using turrax homogeniser for the estimation of captopril levels and ACE-activity.
Analytical procedures
Urine samples were analysed on a Dade Behring BNII using the total protein assay by protein precipitation with 20% TCA. Captopril concentrations were measured in plasma and kidney homogenate by HPLC as described previously. 11 ACE activity was measured in plasma and kidney homogenate at 60 or 240 minutes after the final injection, as described previously. 12
Calculations and statistical analysis
Data for the captopril and captopril-lysozyme treated groups are corrected using data from their respective controls, vehicle, glucose and lysozymetreated animals. All data are presented as mean + S.E.M. Differences in mean values between groups were compared using one-way analysis of variance (ANOVA) and a Bonferroni t-test to identify the groups that were different. In all tests, p<0.05 was considered statistically significant.
Results
All animals completed the study and no differences in growth curves were observed between the groups (data not shown).
Proteinuria
After injection with adriamycin, a stable proteinuria developed, amounting to 547+79 mg/24 hours at 5.5 weeks after induction of renal disease. Upon the start of treatment with captopril and captopril-lysozyme, hardly any effect on proteinuria was found after one and four days of treatment ( Figure 1 ). After seven days of treatment, a slight lowering of proteinuria was observed in the captopril group (-9+10%), although this was not significant, while after nine days of the treatment the decrease in proteinuria in the captopril group was completely blunted. In the captopril-lysozyme conjugate-treated group, a decrease in proteinuria of -35+4% (seven days) and -25+2% (nine days) was found. The reduction in proteinuria was significant at both time points compared with captopril-treated animals, (p<0.05). Furthermore, in the lysozyme-treated group, a slight increase in proteinuria was noticed at days seven and nine (6+13% and 12+8%, respectively).
Blood pressure
The mean of the systolic blood pressure (SBP) measured three and five days before treatment was considered as the baseline measurement.After the onset of the treatment, SBP was measured after two, five and eight days, at 30, 60, 120 and 240 
minutes after the injection in separate rats. As no differences were observed between these time points (data not shown), the data were pooled. Baseline SBP was compared with the average of the three measurements after the start of the treatments. SBP was significantly reduced in the captopril group compared with control (-13.9+2.9 mmHg) ( Figure 2 ). In contrast, the animals in the captoprillysozyme conjugate group showed a trend to an increase in SBP compared with control (7.9+3.3 mmHg). Accordingly, SBP was significantly decreased in captopril-treated animals compared with the captopril-lysozyme conjugate treated group. The animals in the lysozyme group showed a reduction in SBP (-11.5+3.4%), although this was not significant compared with control.
ACE activity
To obtain insight into the efficacy of renal targeting,ACE activity was measured in kidneys collected 60 and 240 minutes after the final injection (Table 1) . After 60 minutes, ACE activity seemed inhibited to a larger extent in the captopril group than in the captopril-lysozyme group, although the difference was not significant. In contrast, after 240 minutes, renal ACE activity was reduced to a similar extent in the captopril-treated group as well as in the captopril-lysozyme conjugate-treated group, compared with control.
Captopril levels
To further investigate renal delivery of captopril, total captopril levels were determined in plasma and kidneys 60 and 240 minutes after the final injection ( Table 2 ). Sixty minutes after the last dose, renal captopril levels did not differ between the captopril group and the captopril-lysozyme group. However, after 240 minutes, there was a significantly higher amount found in the captopril-lysozyme group compared with the captopril group (Table 2) . In contrast to the kidneys, plasma levels of captopril 60 minutes after the final dose were significantly lower in the captopril-lysozyme group compared with the captopril group. After 240 minutes, a significant reduction in captopril levels was found in the captopril group, while those in the captopril-lysozyme group remained at a similar level as observed at 60 minutes.Thus, the percentage of captopril levels in plasma compared to the levels in the kidney 240 minutes after the final dosing is about halved in the captoprillysozyme conjugate group (7.2%) compared with the captopril group (17.3%).
Moreover, the percentage of free plasma captopril was significantly higher in the captopril group compared with the captopril-lysozyme group at 240 minutes (60 minutes: 30.0+6.1% and 18.3+1.6%, 240 minutes and 39.4+4.4% and 21.3+0.8%, respectively). Thus, coupling to lysozyme resulted in about a 50% reduction of the percentage of free captopril in plasma.
Discussion
The aim of the present study was to investigate whether an inferior response to ACE-I under highsodium conditions may be attenuated by targeting the drug to the kidney. Therefore, we studied the effect of captopril-lysozyme conjugate on adriamycin-induced proteinuria in rats fed with a highsodium diet. In these rats, the captopril-lysozyme conjugate significantly reduced proteinuria without affecting blood pressure. In contrast, captopriltreated animals displayed the opposite effect, i.e. a reduction in blood pressure without any effect on proteinuria.Although captopril-lysozyme conjugate was administered at a dose five times lower than captopril, even higher captopril levels were found in the kidneys.These results demonstrate the working profile of the captopril-lysozyme conjugate to be renoselective to an extent that anti-proteinuric effects were observed, without any effect on blood pressure in nephrotic rats on a high sodium diet.
In a previous study employing single injections in healthy animals, subcutaneous (s.c.) injection was shown to be an adequate route of administration to deliver the captopril-lysozyme conjugate, 13 as the conjugate was almost completely absorbed from the injection site, remained stable and displayed a prolonged residence time in the kidneys. Furthermore, the single s.c. dose of captoprillysozyme conjugate produced a moderate but sustained inhibition of renal ACE during the 24-hour observation period, with no effects on plasma ACE. In the present study, we extended these findings to chronic s.c. administration in nephrotic animals. The levels of total captopril that were measured in the current study are in good agreement with those obtained from previous pharmacokinetic data after a single s.c. injection. 13 Furthermore, our data demonstrate a substantial decrease in the percentage of free captopril in plasma by coupling of the drug to lysozyme. Previously, it had been observed that the conjugate does not inhibit plasma ACE. 10 Therefore, it is conceivable that the absence of a blood pressure reduction in the captopril-lysozyme conjugate group is attributable to the lack of inhibition of non-renal ACE. However, the measurement of blood pressure by tail-cuff plethysmography, may have failed to detect minor changes in blood pressure.
The advantage of targeting captopril compared with normal systemic dosing is clearly demonstrated by the observation that higher levels of total renal captopril were achieved, even though the dose of the captopril-lysozyme conjugate was five times lower than that of the parent compound.
Similar to the earlier single dose study with captopril-lysozyme conjugate, 13 the present study, with a 10-day treatment period, shows a moderate (albeit non-significant) inhibition of renal ACE activity (Table 1) . Accordingly, our data demonstrate effective targeting of captopril to the kidney of nephrotic animals by conjugating the drug to lysozyme. Therefore, it is likely that the antiproteinuric effect observed in the captopril-lysozyme conjugate group results from the selective distribution of captopril to the kidneys.
The higher renal levels of total captopril found following the administration of captopril-lysozyme conjugate compared with administration of captopril were accompanied by an antiproteinuric effect in captopril-lysozyme conjugate-treated animals. However, increased renal levels of captopril in the conjugate group did not result in a higher inhibition of renal ACE activity at the time points measured, compared with captopril-treated animals. There may be several explanations for the discrepancy between effects on ACE activity and on proteinuria. First, the antiproteinuric effect represents the effectiveness of the drug during a 24hour period, while ACE activity was measured at specific time points.As conjugation of captopril to lysozyme apparently prolongs the drug's half-life in renal tissue, renal ACE activity may simply be inhibited for a longer period of time as a result of conjugation. Secondly, drug levels measured in the captopril-lysozyme conjugate group represent total captopril levels, i.e. both conjugated and unconjugated drug.The thiol group of captopril is conjugated with lysozyme; however, this group is essential for the ACE-I action of captopril. 14 So, before the coupled captopril can be active, it must be uncoupled in the kidney, probably by reduced glutathione. 9 Kok et al. 9 found that the majority of an intravenous dose of captopril-lysozyme conjugate was accumulated in the kidney in the first hour, while the relative amount of free captopril rose during the three-hour period after injection to 21% of the total captopril concentration. This feature of the captopril-lysozyme conjugate may explain the discrepancy between the total renal captopril concentration measured and the renal ACE activity measured.Thirdly, distribution of the drug within the kidney may differ when administered as captopril-lysozyme conjugate. Following glomerular secretion, captopril-lysozyme conjugate is selectively taken up by tubular cells via receptor-mediated endocytosis. 15 The majority of ACE in the kidney is localised in the brush border of the proximal and distal tubular cells of the cortex and in the glomeruli. 16, 17 In overt proteinuria, ACE and angiotensinogen are both up-regulated in the proximal renal tubules. 16 As previously noted, captopril-lysozyme conjugate is selectively reabsorbed in the tubular cells and uncoupled by intracellular glutathione. Therefore, the captopril released from the conjugate at the level of tubular cells may be responsible for the antiproteinuric effect observed in the captopril-lysozyme conjugate group. It could be that ACE present in cells other than tubular cells, such as endothelial cells, is not inhibited in the captopril-lysozyme group, while it is in the captopril group. Therefore, the total ACE-I would be lower in the captoprillysozyme group, while tubular ACE is inhibited to the same extent. The antiproteinuric effect of ACE-I develops slowly 18 and usually takes five weeks of treatment to reach its maximal effect. In the present study, we treated the animals with captopril-lysozyme conjugate for nine days. However, it is likely that, after nine days of treatment, the maximal antiproteinuric effect had not yet been achieved, indicating the need for further research into the efficacy of long-term treatment with captopril-lysozyme conjugate.
The results of previous clinical studies and animal experiments showed that an increase in sodium intake blunts the antiproteinuric effect of ACE-I. 5, 7, 8, 19 As sodium intake itself has no influence on proteinuria in adriamycin-induced nephrosis, 8 the efficacy of captopril-lysozyme conjugate in animals fed a high-sodium diet is likely the result of improved pharmacokinetic or dynamic properties of the drug. The most obvious explanation would be a change in the kinetic parameters of captopril as a result of coupling to lysozyme, in view of the prolonged residence time in the kidney. However, in the present study we cannot exclude a different pharmacodynamic profile of the drug.
In this study, we demonstrated that drug targeting provides a feasible method to treat nephrosis. Targeting of captopril to the kidney has some important benefits: it is devoid of reductions in blood pressure and it has an antiproteinuric effect, even in conditions of high-sodium load. In general, blood pressure reduction is sought in therapy of proteinuric renal disease. In this perspective, conjugation of the ACE-I does not seem to have any advantage, as the blood pressure reduction is lost. Recent evidence suggests that the anti-proteinuric effect of the systemic administration of ACE-I is enhanced by dose increase or by combination with an angiotensin receptor blocker (ARB). 20 In these situations, over-reduction of blood pressure may limit the potential to obtain optimal antiproteinuric effects. Under these circumstances, conjugation of ACE-I to lysozyme may allow renal titration of ACE-I without causing systemic side-effects, such as hypotension.
Because of the chemical limitations of ACE-I with more potent antiproteinuric efficacy, captopril had to be used in the present drug targeting approach. In spite of this, the conjugate displayed antiproteinuric effects at a very low dose. Nevertheless, future research will need to disclose strategies to couple more potent ACE-I to a small protein carrier, to avoid administration of large amounts of lysozyme.
Conclusions
Our results show that in adriamycin nephrotic rats fed a high-sodium diet, s.c. injection with captopril-lysozyme conjugate induced an antiproteinuric effect without reduction of blood pressure. In contrast, a five-times higher dose of s.c. captopril had no antiproteinuric effect, but did reduce blood pressure.ACE-I-lysozyme conjugate provides a valuable tool to further study ways of enhancing efficacy and improving on response variability of ACE-I for renoprotection. 
